{
    "thesis_theoretical": [
        {
            "Thesis0": "The influencer suggests that the company's strong fundamentals and high growth rate are the key reasons for its impressive returns."
        },
        {
            "Thesis1": "The influencer also points out that despite the stock's significant growth, it is still undervalued based on its PE and PEG ratios."
        },
        {
            "Thesis2": "The influencer suggests that the company has the potential to become a mid or large cap stock in the future."
        }
    ],
    "thesis_quantitative": [
        {
            "Thesis0": "In the last five years, the stock has given close to 2200% returns."
        },
        {
            "Thesis1": "In the last few years, the company's revenues have been growing at a rate of 26-30%."
        },
        {
            "Thesis2": "The company's earnings per share has been growing at a rate of 44-32%."
        },
        {
            "Thesis3": "The stock's PE is currently at 19, compared to Nifty Pharma PE which is roughly at 31."
        },
        {
            "Thesis4": "The PEG ratio of the stock is currently 0.27."
        }
    ],
    "username": "Rahul Jain"
}